Full-Time

Associate Director

Procurement Policy and Process

Otsuka Pharmaceutical

Otsuka Pharmaceutical

1,001-5,000 employees

Global pharma maker of Abilify

Compensation Overview

$150k - $224.3k/yr

+ Incentive opportunity

Princeton, NJ, USA

In Person

Bachelor's, Master's, MBA

Category
Operations & Logistics (1)
Required Skills
LLM
ERP
Data Visualization
SAP Products
Financial analysis
Risk Management
Data Analysis

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Requirements
  • A minimum of 8+ years of diverse experience in varying procurement roles.
  • Deep knowledge of Source to Pay processes and best practices, including SAP Ariba.
  • Strong understanding of procurement compliance, risk management, and regulatory requirements within the pharmaceutical industry.
  • Familiarity with procurement technology platforms.
  • Ability to design and implement metrics, service-level agreements, and scorecards.
  • Strong procurement operations and process management experience.
  • Experience with Source to Pay processes, strategic sourcing, enterprise resource planning systems, procurement analytics, and operational excellence.
  • Strong understanding of the pharmaceutical industry and the development and commercialization of new drugs.
  • A Bachelor's degree in Business, Supply Chain, or relevant technical expertise.
Responsibilities
  • Support the development and implementation of procurement strategies aligned with organizational goals, forecast needs, and manage the procurement planning process.
  • Ensure compliance with federal, state, and local laws, regulations, and organizational policies related to procurement, including taxability of goods and services.
  • Develop, update, and enforce procurement policies, procedures, and standard operating guidelines in line with regulatory requirements, corporate governance, and best practices.
  • Support maintenance and administration for procurement-related compliance issues.
  • Partner with Sourcing, Legal, Compliance, Information Security, Finance, and Quality to embed regulatory risks and controls into the purchasing process.
  • Identify and recommend process improvement initiatives to streamline the end-to-end Source to Pay process, including sourcing, contracting, purchasing, and supplier management.
  • Partner with Sourcing and Vendor Management professionals to evaluate and manage supplier relationships and ways of working.
  • Administer and maintain approval workflows, delegation-of-authority thresholds, and control mechanisms to mitigate risk while enabling efficient business operations.
  • Implement standardized templates, RACI matrices, and playbooks to ensure consistency across companies and purchasing categories.
  • Develop and distribute monthly success metrics across the Source to Pay process.
  • Provide training and guidance to the internal Procurement team and business partners on procurement policies and procedures.
  • Collaborate with business stakeholders to support procurement processes aligned with business objectives and operational needs.
  • Support change management efforts to drive stakeholder adoption.
  • Collaborate with Information Technology to prioritize and define system requirements, workflows, and controls within procurement platforms.
  • Support operational excellence initiatives across Source to Pay, emphasizing automation, lean processes, and continuous improvement in conjunction with Information Technology.
  • Build business cases and success measures for major system enhancements.
  • Ensure procurement master-data cleanliness, develop compliance reporting, and ensure adequate audit trails.
  • Establish key performance indicators and dashboards powered by advanced analytics for spend, performance, cycle times, and savings tracking.
  • Support adoption of generative artificial intelligence and advanced analytics to automate purchasing processes and performance reporting.
  • Manage seamless transitions and process integrations, especially across affiliated companies and acquisitions.
  • Monitor supplier and contract compliance with company policies and regulatory requirements.
  • Support internal and external audits by ensuring adequate documentation, approvals, and governance controls are in place.
  • Proactively identify gaps and emerging risks in current procurement practices and recommend corrective actions.
Desired Qualifications
  • An advanced degree such as a Master of Business Administration or Master of Science is preferred.
  • Experience with successful delivery of transformative projects.
  • Proficiency in artificial intelligence and analytics tools, generative artificial intelligence platforms, and digital storytelling.
  • Strategic mindset with financial acumen to assess return on investment and cost-benefit for process improvements.
Otsuka Pharmaceutical

Otsuka Pharmaceutical

View

Otsuka Pharmaceutical develops and markets medicines and health products worldwide, including prescription drugs and nutraceutical beverages. Its product lineup ranges from pharmaceutical treatments such as Abilify (an antipsychotic) to consumer health drinks like Pocari Sweat, which helps replenish electrolytes. Abilify works as a psychiatric medication used to treat conditions such as schizophrenia and bipolar disorder, while Pocari Sweat is an ion-replacement beverage designed to restore minerals and fluids after activity or heat. The company differentiates itself through a long history dating back to its founding in 1921, a broad, globally scaled portfolio spanning drugs and health beverages, and a focus on health improvements across populations. Its stated goal is to create new products for better health worldwide.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1921

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • VOYXACT’s July 2026 VISIONARY data showed two-year eGFR stabilization and kidney-failure risk reduction.
  • SIMTRIYO cleared FDA review on July 24, 2026, opening a large ADHD market.
  • Japan covered Paradise renal denervation on March 1, 2026, accelerating cardiovascular device revenue.

What critics are saying

  • VOYXACT remains accelerated-approval dependent until the FDA accepts its confirmatory 2026 traditional filing.
  • SIMTRIYO cannot launch until DEA scheduling, delaying cash collection and ceding early prescriptions.
  • Otsuka still depends on a few launches; VOYXACT failure or Simtriyo slowdown would crush growth.

What makes Otsuka Pharmaceutical unique

  • SIMTRIYO became Otsuka’s first U.S. ADHD launch, expanding its CNS franchise on July 24, 2026.
  • VOYXACT gave Otsuka first U.S. APRIL inhibition and traditional-approval runway in IgAN.
  • Astex’s fragment-based platform secured Genentech’s breast-cancer pact on July 6, 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Tuition Reimbursement

Student Loan Assistance

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Associated Press
Jul 25th, 2026
FDA approves Otsuka's Simtriyo, first-in-class ADHD treatment for adults and children 6+

Otsuka Pharmaceutical has received FDA approval for SIMTRIYO (centanafadine), the first norepinephrine, dopamine, serotonin reuptake inhibitor for treating ADHD in adults and children aged six years and older weighing at least 20kg. The once-daily extended-release capsule will be available later this year following DEA scheduling. The approval is based on four Phase 3 clinical trials showing statistically significant improvements in ADHD symptoms compared to placebo, with benefits observed as early as week one. Common side effects include decreased appetite, nausea, rash, and headache. ADHD affects approximately 7 million children and 15.5 million adults in the US. The drug carries boxed warnings for suicidal ideation in pediatric patients and potential for abuse and addiction.

SonoThera
Jun 10th, 2026
SonoThera Closes Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Ultrasound-Mediated Nonviral Genetic Medicines - SonoThera

SAN FRANCISCO–SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, today announced the closing of an oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines.

Dealroom.co
Mar 27th, 2026
Transcend Therapeutics company information, funding & investors

Transcend Therapeutics, developing the next generation of psychoactive compounds for neuropsychiatry focused on patient access. Here you'll find information about their funding, investors and team.

Fierce Biotech
Mar 27th, 2026
Otsuka buys Transcend Therapeutics for $700M upfront in psychiatric drugs deal

Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its subsidiary Otsuka America, with potential milestone payments of up to $525 million. The deal gives Otsuka access to Transcend's MDMA analogue for psychiatric conditions currently in development.

Associated Press
Mar 25th, 2026
Otsuka's Voyxact shows 82.5% hematuria improvement in IgA nephropathy trial at 48 weeks

Otsuka presented new Phase 3 VISIONARY trial data for VOYXACT (sibeprenlimab-szsi) in IgA nephropathy patients at the 2026 ISN World Congress of Nephrology. The analyses showed 82.5% of patients receiving sibeprenlimab achieved negative microscopic hematuria at week 48, compared with 52.6% on placebo. Median time to achieve hematuria negativity was nine weeks versus 24 weeks for placebo. VOYXACT, approved under accelerated approval in the US, is a monoclonal antibody that inhibits APRIL, a key driver in IgAN pathogenesis. Previously reported data showed the drug met its primary endpoint with a 51.2% placebo-adjusted reduction in proteinuria at nine months. The trial continues evaluating sibeprenlimab's effect on preserving kidney function over 24 months.